{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:32:00Z","timestamp":1792503120173,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C1994\/A28701"],"award-info":[{"award-number":["C1994\/A28701"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C1994\/A28701"],"award-info":[{"award-number":["C1994\/A28701"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C1994\/A28701"],"award-info":[{"award-number":["C1994\/A28701"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Given limited and conflicting data, this systematic review and meta-analysis investigate the impacts of statin use on survival outcomes and adverse events in patients with cancer receiving radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of MEDLINE, EMBASE, Web of Science, Scopus, and PubMed (January 2000 to June 2024) included studies on adults (\u2265\u200918 years) with histologically confirmed cancer receiving oral statins during radiotherapy. Overall survival (OS) rates and radiotherapy-related adverse effects were compared between statin users and non-users using odds ratios (ORs) and 95% confidence intervals (95%CIs). Meta-regression explored the effects of cancer type and statin intensity on OS rates, reported as coefficients (\u03b2) and 95%CI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 21 studies (19 cohort studies and two randomized trials), OS rates did not significantly differ between statin users and non-users (OR: 1.29; 95%CI: 0.99, 1.69) or by statin intensity (\u03b2: 0.20; 95%CI: -1.22, 1.62;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.60), but significantly by cancer types (\u03b2: -0.29; 95%CI: -0.45, -0.13;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Statin use was associated with improved survival in oesophageal squamous cell carcinoma (SCC), head and neck SCC, glioblastoma, and prostate cancer, but with reduced survival in non-small cell lung cancer (NSCLC) and brain metastases. Statin users had a higher risk of major adverse cardiac events (OR: 2.22; 95%CI: 1.38, 3.59) in NSCLC and \u2265\u2009grade 2 mucositis (OR: 26.00; 95%CI: 4.09, 165.10) in head and neck squamous cell carcinoma but lower risks of ischemic stroke (OR: 0.80; 95%CI: 0.67, 0.95) in nasopharyngeal carcinoma and rectal toxicity (OR: 0.45; 95%CI: 0.23, 0.88) in prostate cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Survival outcomes did not significantly differ by statin use or intensity but varied by cancer type. Statin users had lower risks of ischemic stroke and rectal toxicity. Further studies are needed to control for confounding biases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>PROSPERO registration CRD42023487336.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15038-3","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:45:13Z","timestamp":1761734713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of statin use on survival and adverse events in patients with cancer receiving radiotherapy: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-0558","authenticated-orcid":false,"given":"Hala","family":"Shokr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Chuen","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaye Janine","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"7","key":"15038_CR1","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1016\/S1470-2045(15)00080-7","volume":"16","author":"TW LeBlanc","year":"2015","unstructured":"LeBlanc TW, McNeil MJ, Kamal AH, Currow DC, Abernethy AP. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol. 2015;16(7):e333\u201341.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15038_CR2","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1038\/s41467-024-47002-3","volume":"15","author":"E Dumas","year":"2024","unstructured":"Dumas E, Grandal Rejo B, Gougis P, Houzard S, Abecassis J, Jochum F, et al. Concomitant medication, comorbidity and survival in patients with breast cancer. Nat Commun. 2024;15(1):2966.","journal-title":"Nat Commun"},{"issue":"4","key":"15038_CR3","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1177\/1078155219875210","volume":"26","author":"S Maleki","year":"2019","unstructured":"Maleki S, Alexander M, Liu C, Rischin D, Lingaratnam S, Fua T. Radiation oncology outpatient medication management needs and service gaps-a cross-sectional study of patients and clinicians. J Oncol Pharm Pract. 2019;26(4):846\u201352.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"15038_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1124\/pr.111.004994","volume":"64","author":"P Gazzerro","year":"2012","unstructured":"Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64(1):102\u201346.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"15038_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic effects of Statins on the cardiovascular system. Circ Res. 2017;120(1):229\u201343.","journal-title":"Circ Res"},{"issue":"3","key":"15038_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00228-021-03250-6","volume":"78","author":"Rodr\u00edguezLA Garc\u00eda","year":"2022","unstructured":"Garc\u00eda Rodr\u00edguezLA, Cea Soriano L, de Abajo FJ, Valent F, Hallas J, Gil M, et al. Trends in the use of oral anticoagulants, antiplatelets and Statins in four European countries: a population-based study. Eur J Clin Pharmacol. 2022;78(3):497\u2013504.","journal-title":"Eur J Clin Pharmacol"},{"issue":"13","key":"15038_CR7","doi-asserted-by":"publisher","first-page":"e005996","DOI":"10.1161\/JAHA.117.005996","volume":"8","author":"J Boulet","year":"2019","unstructured":"Boulet J, Pe\u00f1a J, Hulten EA, Neilan TG, Dragomir A, Freeman C, et al. Statin use and risk of vascular events among cancer patients after radiotherapy to the thorax, head, and neck. J Am Heart Assoc. 2019;8(13):e005996.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"15038_CR8","first-page":"1055","volume":"23","author":"M Jakobisiak","year":"2003","unstructured":"Jakobisiak M, Golab J. Potential antitumor effects of Statins (Review). Int J Oncol. 2003;23(4):1055\u201369.","journal-title":"Int J Oncol"},{"issue":"3","key":"15038_CR9","doi-asserted-by":"publisher","first-page":"101722","DOI":"10.1016\/j.jgo.2024.101722","volume":"15","author":"DT O\u2019Sullivan","year":"2024","unstructured":"O\u2019Sullivan DT, Walsh DJ, Goggin C, Horgan AM. Statin use in older adults with cancer-experience from a dedicated geriatric oncology service. J Geriatr Oncol. 2024;15(3):101722.","journal-title":"J Geriatr Oncol"},{"issue":"11","key":"15038_CR10","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrc.2016.76","volume":"16","author":"PJ Mullen","year":"2016","unstructured":"Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016;16(11):718\u201331.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"15038_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3892\/or.2015.3741","volume":"33","author":"AK Altwairgi","year":"2015","unstructured":"Altwairgi AK. Statins are potential anticancerous agents. Oncol Rep. 2015;33(3):1019\u201339.","journal-title":"Oncol Rep"},{"issue":"5","key":"15038_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2174\/1871520613666131129105035","volume":"14","author":"GN Vallianou","year":"2014","unstructured":"Vallianou GN, Kostantinou A, Kougias M, Kazazis C. Statins and cancer. Anticancer Agents Med Chem. 2014;14(5):706\u201312.","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"15038_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/bmb\/ldq044","volume":"97","author":"G Fritz","year":"2011","unstructured":"Fritz G, Henninger C, Huelsenbeck J. Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents. Br Med Bull. 2011;97(1):17\u201326.","journal-title":"Br Med Bull"},{"key":"15038_CR14","doi-asserted-by":"publisher","first-page":"110067","DOI":"10.1016\/j.radonc.2023.110067","volume":"191","author":"CY Lin","year":"2024","unstructured":"Lin CY, Chang CL, Lin KC, Chen WM, Shia BC, Kuo PH, et al. Statin use reduces radiation-induced stroke risk in advanced nasopharyngeal carcinoma patients. Radiother Oncol. 2024;191:110067.","journal-title":"Radiother Oncol"},{"issue":"2","key":"15038_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.brachy.2014.05.019","volume":"14","author":"J Cuaron","year":"2015","unstructured":"Cuaron J, Pei X, Cohen GN, Cox BW, Yamada Y, Zelefsky MJ, et al. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. Brachytherapy. 2015;14(2):179\u201384.","journal-title":"Brachytherapy"},{"issue":"14","key":"15038_CR16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ejca.2011.12.034","volume":"48","author":"LJ Wedlake","year":"2012","unstructured":"Wedlake LJ, Silia F, Benton B, Lalji A, Thomas K, Dearnaley DP, et al. Evaluating the efficacy of Statins and ACE-inhibitors in reducing Gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies. Eur J Cancer. 2012;48(14):2117\u201324.","journal-title":"Eur J Cancer"},{"issue":"1","key":"15038_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s10637-020-00992-5","volume":"39","author":"AK Altwairgi","year":"2021","unstructured":"Altwairgi AK, Alghareeb WA, AlNajjar FH, Alhussain H, Alsaeed E, Balbaid AAO, et al. Atorvastatin in combination with radiotherapy and Temozolomide for glioblastoma: a prospective phase II study. Invest New Drugs. 2021;39(1):226\u201331.","journal-title":"Invest New Drugs"},{"issue":"1","key":"15038_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.urology.2008.02.055","volume":"73","author":"DE Soto","year":"2009","unstructured":"Soto DE, Daignault S, Sandler HM, Ray ME. No effect of Statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urol. 2009;73(1):158\u201362.","journal-title":"Urol"},{"issue":"4","key":"15038_CR19","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.ijrobp.2011.09.042","volume":"83","author":"M Alizadeh","year":"2012","unstructured":"Alizadeh M, Sylvestre MP, Zilli T, Van Nguyen T, Guay JP, Bahary JP, et al. Effect of Statins and anticoagulants on prostate cancer aggressiveness. Int J Radiat Oncol Biol Phys. 2012;83(4):1149\u201353.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"15038_CR20","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1200\/JCO.2009.27.3003","volume":"28","author":"R Gutt","year":"2010","unstructured":"Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010;28(16):2653\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"15038_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1464-410X.2010.09232.x","volume":"106","author":"MS Katz","year":"2010","unstructured":"Katz MS, Carroll PR, Cowan JE, Chan JM, D\u2019Amico AV. Association of Statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from capsure. BJU Int. 2010;106(5):627\u201332.","journal-title":"BJU Int"},{"issue":"3","key":"15038_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ijrobp.2009.12.006","volume":"79","author":"MA Kollmeier","year":"2011","unstructured":"Kollmeier MA, Katz MS, Mak K, Yamada Y, Feder DJ, Zhang Z, et al. Improved biochemical outcomes with Statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79(3):713\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"15038_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4236\/jct.2017.82007","volume":"8","author":"X Liu","year":"2017","unstructured":"Liu X, Li J, Schild SE, Schild MH, Wong W, Vora S, et al. Statins and Metformin use is associated with lower PSA levels in prostate cancer patients presenting for radiation therapy. J Cancer Ther. 2017;8(2):73\u201385.","journal-title":"J Cancer Ther"},{"issue":"1","key":"15038_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00345-014-1281-x","volume":"33","author":"DS Oh","year":"2015","unstructured":"Oh DS, Koontz B, Freedland SJ, Gerber L, Patel P, Lewis S, et al. Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. World J Urol. 2015;33(1):93\u20137.","journal-title":"World J Urol"},{"issue":"3","key":"15038_CR25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.21873\/anticanres.11469","volume":"37","author":"I Palumbo","year":"2017","unstructured":"Palumbo I, Matrone F, Montesi G, Bellavita R, Lupattelli M, Saldi S, et al. Statins protect against acute RT-related rectal toxicity in patients with prostate cancer: an observational prospective study. Anticancer Res. 2017;37(3):1453\u20137.","journal-title":"Anticancer Res"},{"key":"15038_CR26","doi-asserted-by":"publisher","first-page":"109762","DOI":"10.1016\/j.radonc.2023.109762","volume":"186","author":"GM Walls","year":"2023","unstructured":"Walls GM, O\u2019Connor J, Harbinson M, McCarron EP, Duane F, McCann C, et al. Association between Statin therapy dose intensity and radiation cardiotoxicity in non-small cell lung cancer: results from the NI-HEART study. Radiother Oncol. 2023;186:109762.","journal-title":"Radiother Oncol"},{"issue":"2","key":"15038_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.rpor.2019.12.027","volume":"25","author":"G Cadeddu","year":"2020","unstructured":"Cadeddu G, Herv\u00e1s-Mor\u00f3n A, Mart\u00edn-Mart\u00edn M, Pelari-Mici L, Ytuza-Charahua de Kirsch K, Hern\u00e1ndez-Corrales A, et al. Metformin and statins: a possible role in high-risk prostate cancer. Rep Pract Oncol Radiother. 2020;25(2):163\u20137.","journal-title":"Rep Pract Oncol Radiother"},{"key":"15038_CR28","doi-asserted-by":"publisher","first-page":"184297","DOI":"10.1155\/2014\/184297","volume":"2014","author":"J Caon","year":"2014","unstructured":"Caon J, Paquette M, Hamm J, Pickles T. Does Statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy? Prostate Cancer. 2014;2014:184297.","journal-title":"Prostate Cancer"},{"issue":"1","key":"15038_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.canlet.2013.02.017","volume":"335","author":"C Chao","year":"2013","unstructured":"Chao C, Williams SG, Xu L, Chen J, Wallner LP, Porter KR, et al. Statin therapy is not associated with prostate cancer recurrence among patients who underwent radiation therapy. Cancer Lett. 2013;335(1):214\u20138.","journal-title":"Cancer Lett"},{"issue":"4","key":"15038_CR30","first-page":"298","volume":"26","author":"MA Moyad","year":"2006","unstructured":"Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Butler EG, et al. Statins, especially atorvastatin, May improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs. 2006;26(4):298\u2013303.","journal-title":"Urol Nurs"},{"issue":"8","key":"15038_CR31","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jtho.2023.04.005","volume":"18","author":"WM Chen","year":"2023","unstructured":"Chen WM, Yu YH, Chen M, Shia BC, Wu SY. Statin use during concurrent chemoradiotherapy with improved survival outcomes in esophageal squamous cell carcinoma: a propensity score-matched nationwide cohort study. J Thorac Oncol. 2023;18(8):1082\u201393.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"15038_CR32","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65\u201394.","journal-title":"Ann Intern Med"},{"issue":"6","key":"15038_CR33","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3727\/096504016X14719078133528","volume":"24","author":"M El-Hamamsy","year":"2016","unstructured":"El-Hamamsy M, Elwakil H, Saad AS, Shawki MA. A randomized controlled ppen-label pilot study of Simvastatin addition to whole-brain radiation therapy in patients with brain metastases. Oncol Res. 2016;24(6):521\u20138.","journal-title":"Oncol Res"},{"issue":"5","key":"15038_CR34","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/j.prro.2020.12.006","volume":"11","author":"KM Atkins","year":"2021","unstructured":"Atkins KM, Bitterman DS, Chaunzwa TL, Williams CL, Rahman R, Kozono DE, et al. Statin use, heart radiation dose, and survival in locally advanced lung cancer. Pract Radiat Oncol. 2021;11(5):e459\u201367.","journal-title":"Pract Radiat Oncol"},{"issue":"9326","key":"15038_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF heart protection study of cholesterol Lowering with Simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360(9326):7\u201322.","journal-title":"Lancet"},{"issue":"2","key":"15038_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155\u201363.","journal-title":"J Chiropr Med"},{"key":"15038_CR37","unstructured":"The National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. 2023. Available from: https:\/\/www.nice.org.uk\/guidance\/ng238\/chapter\/recommendations#low-intensity-statin"},{"issue":"25","key":"15038_CR38","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2018","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circ. 2018;139(25):e1082\u2013143.","journal-title":"Circ."},{"key":"15038_CR39","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"15038_CR40","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"issue":"15suppl","key":"15038_CR41","doi-asserted-by":"publisher","first-page":"e18222","DOI":"10.1200\/JCO.2019.37.15_suppl.e18222","volume":"37","author":"A Lipitz-Snyderman","year":"2019","unstructured":"Lipitz-Snyderman A, Curry MA, Rubin DM, Li DG, Duck E, Radzyner MH, et al. A conundrum in cancer quality measurement: performance on long-term survival reflects performance a long time ago. J Clin Oncol. 2019;37(15suppl):e18222\u2013e.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15038_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/1536867X1001000307","volume":"10","author":"E Kontopantelis","year":"2010","unstructured":"Kontopantelis E, Reeves D. Metaan: random-effects meta-analysis. Stata J. 2010;10(3):395\u2013407.","journal-title":"Stata J"},{"issue":"2","key":"15038_CR43","first-page":"117","volume":"15","author":"A Sharifian","year":"2024","unstructured":"Sharifian A, Aghili M. The role of Lovastatin in curative chemoradiotherapy for patients with head and neck cancer: a randomized trial. Middle East J Cancer. 2024;15(2):117\u201327.","journal-title":"Middle East J Cancer"},{"issue":"10","key":"15038_CR44","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.3390\/cancers12102724","volume":"12","author":"R Giampieri","year":"2020","unstructured":"Giampieri R, Cantini L, Giglio E, Bittoni A, Lanese A, Crocetti S, et al. Impact of polypharmacy for chronic ailments in colon cancer patients: a review focused on drug repurposing. Cancers. 2020;12(10):2724.","journal-title":"Cancers"},{"issue":"12","key":"15038_CR45","doi-asserted-by":"publisher","first-page":"e0209486","DOI":"10.1371\/journal.pone.0209486","volume":"13","author":"MAM Farooqi","year":"2018","unstructured":"Farooqi MAM, Malhotra N, Mukherjee SD, Sanger S, Dhesy-Thind SK, Ellis P, et al. Statin therapy in the treatment of active cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2018;13(12):e0209486.","journal-title":"PLoS ONE"},{"issue":"14","key":"15038_CR46","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1002\/cncr.25308","volume":"116","author":"RJ Hamilton","year":"2010","unstructured":"Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy. Cancer. 2010;116(14):3389\u201398.","journal-title":"Cancer"},{"issue":"4","key":"15038_CR47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2015.0829","volume":"1","author":"LC Harshman","year":"2015","unstructured":"Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol. 2015;1(4):495\u2013504.","journal-title":"JAMA Oncol"},{"issue":"40","key":"15038_CR48","doi-asserted-by":"publisher","first-page":"42988","DOI":"10.18632\/oncotarget.5557","volume":"6","author":"QJ Wu","year":"2015","unstructured":"Wu QJ, Tu C, Li YY, Zhu J, Qian KQ, Li WJ, et al. Statin use and breast cancer survival and risk: a systematic review and meta-analysis. Oncotarget. 2015;6(40):42988\u20133004.","journal-title":"Oncotarget"},{"issue":"6","key":"15038_CR49","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/ijc.30185","volume":"139","author":"S Manthravadi","year":"2016","unstructured":"Manthravadi S, Shrestha A, Madhusudhana S. Impact of Statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. Int J Cancer. 2016;139(6):1281\u20138.","journal-title":"Int J Cancer"},{"issue":"2","key":"15038_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","volume":"104","author":"EJ Mills","year":"2011","unstructured":"Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of Statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM. 2011;104(2):109\u201324.","journal-title":"QJM"},{"issue":"12","key":"15038_CR51","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","volume":"15","author":"BB Adhyaru","year":"2018","unstructured":"Adhyaru BB, Jacobson TA. Safety and efficacy of Statin therapy. Nat Rev Cardiol. 2018;15(12):757\u201369.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"15038_CR52","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3390\/ijms21051897","volume":"21","author":"H Jang","year":"2020","unstructured":"Jang H, Kwak SY, Park S, Kim K, Kim Yh, Na J, et al. Pravastatin alleviates radiation proctitis by regulating thrombomodulin in irradiated endothelial cells. Int J Mol Sci. 2020;21(5):1897.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15038-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:37:54Z","timestamp":1781613474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15038-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15038"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15038-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1666"}}